


ANILINE-DERIVED LIGANDS FOR THE THYROID RECEPTORAbstract of the Disclosure

5 New thyroid receptor ligands are provided which have the general formula



in which:

X is -O-, -S-, -CH₂-, -CO-, or -NH-;

10 Y is -(CH₂)_n- where n is an integer from 1 to 5, or cis- or trans-ethylene;

R₁ is halogen, trifluoromethyl, or alkyl of 1 to 6 carbons or cycloalkyl of 3 to 7 carbons;

15 R₂ and R₃ are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 6 carbons, at least one of R₂ and R₃ being other than hydrogen;

R₄ is hydrogen or lower alkyl;

R₅ is hydrogen or lower alkyl;

20 R₆ is carboxylic acid, or esters or prodrugs;

R₇ is hydrogen or an alkanoyl or an aroyl.

In addition, a method is provided for preventing, inhibiting or treating a disease associated with metabolism dysfunction or which is dependent upon the expression of a T₃ regulated gene, wherein a compound as described above is administered in a therapeutically effective amount. Examples of such diseases associated with metabolism dysfunction or are dependent upon the expression of a T₃ regulated gene include obesity, hypercholesterolemia, atherosclerosis, cardiac arrhythmias, depression, osteoporosis, hypothyroidism, goiter, thyroid cancer as well as glaucoma, congestive heart failure and skin disorders.

25
30